Bone densitometry company Hologic introduced two new digital general radiography systems this month at the RSNA show. Epex and Radex are based on DirectRay solid-state electronic and semiconductor technologies to capture x-rays. Epex is a high-end unit,
Bone densitometry company Hologic introduced two new digital general radiography systems this month at the RSNA show. Epex and Radex are based on DirectRay solid-state electronic and semiconductor technologies to capture x-rays. Epex is a high-end unit, while Radex is a simpler system designed for the outpatient market. Both units will be installed in clinical facilities during the second quarter of 2000.
The two new units round out the Bedford, MA, companys product line, which also includes its DR1000C digital chest system and DR1000 general radiography system. DR1000C units have been installed in five European countries, as well as at sites in Canada and the U.S., and Hologic made its first clinical installations of DR1000 in November.
In other Hologic news, the firm has established a new organizational structure for bringing its systems to market: Hologic will design, market, and service its radiographic products, while its subsidiary, Direct Radiography Corp. (DRC), will be responsible for designing, manufacturing, and servicing DirectRay detectors. DRC will market the detectors as fully integrated Hologic radiographic systems, as a digital image capture upgrade for existing x-ray equipment sold through distributors, and as a component for OEMs.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.